Artificial blood business for animal* transfusion
*Dogs and Cats

• Development of red blood cells (RBC) for blood transfusion in companion animals from animal immortalized adult erythroid progenitors
• Growing demand for animal plasma products and derivatives accounted for $1.04 billion in 2015 and analysts predict that this market opportunity will increase at a CAGR of 6.5% between 2016 and 2024, and by the end of 2027 estimated to reach a value of $1.8 billion (source: Research and Market) RedGene is aiming to reach the estimated cultured RBC market sale at about $30 million in 2027.